Systemic and local high mobility group box 1 concentrations during severe infection

Critical Care Medicine

Volumn 35, Issue 12, 2007, Pages 2799-2804

  Van Zoelen, Marieke A D ^a   Laterre, Pierre François ^b   Van Veen, Suzanne Q ^a   Van Till, Jan W O ^a   Wittebole, Xavier ^b   Bresser, Paul ^a   Tanck, Michael W ^a   Dugernier, Thierry ^c   Ishizaka, Akitoshi ^d   Boermeester, Marja A ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Clinique Saint Pierre of Ottignies   (Belgium)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Cytokines; High mobility group box 1; Peritonitis; Pneumonia; Sepsis; Urinary tract infection

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HUMAN; INFECTION; INTENSIVE CARE UNIT; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL; URINARY TRACT INFECTION;

EID: 36448975877     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000287588.69000.97     Document Type: Article

References (34)

1. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
3. Annane D, Aegerter P, Jars-Guincestre MC, et al: Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172
4. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
5. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient: High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
6. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420:885-891
7. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
8. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
9. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004; 101:296-301
10. Qin S, Wang H, Yuan R, et al: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637-1642
11. Suda K, Kitagawa Y, Ozawa S, et al: Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006; 30:1755-1762
12. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33:564-573
13. Ueno H, Matsuda T, Hashimoto S, et al: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170:1310-1316
14. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
15. van Till JW, Levi M, Bresser P, et al: Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J Infect Dis 2006; 194:1331-1339
16. Rijneveld AW, Weijer S, Bresser P, et al: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34:1725-1730
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
18. Yamada S, Inoue K, Yakabe K, et al: High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 2003; 49:1535-1537
19. Yamada S, Yakabe K, Ishii J, et al: New high mobility group box 1 assay system. Clin Chim Acta 2006; 372:173-178
20. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5:331-342
21. Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-570
22. Fiuza C, Bustin M, Talwar S, et al: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101:2652-2660
23. Sappington PL, Yang R, Yang H, et al: HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123:790-802
24. Ulloa L, Ochani M, Yang H, et al: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002; 99:12351-12356
25. Wang H, Liao H, Ochani M, et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216-1221
26. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-822
27. Hotchkiss RS, Chang KC, Swanson PE, et al: Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nat Immunol 2000; 1:496-501
28. Hatada T, Wada H, Nobori T, et al: Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94:975-979
29. Gaïni S, Pedersen SS, Koldkjaer OG, et al: High mobility group box-1 in patients with suspected community-acquired infections and sepsis: A prospective study. Crit Care 2007; 11:R32
30. Dumitriu IE, Baruah P, Manfredi AA, et al: HMGB1: Guiding immunity from within. Trends Immunol 2005; 26:381-387
31. Bonaldi T, Talamo F, Scaffaldi P, et al: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22:5551-5560
32. Abraham E, Arcaroli J, Carmody A, et al: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165:2950-2954
33. Kim JY, Park JS, Strassheim D, et al: HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005; 288:958-965
34. Ogawa EN, Ishizaka A, Tasaka S, et al: Contribution of high mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med 2006; 17:400-407